Vitamin C Classes Blast Bid To Nix $153M Antitrust Verdict

Law360, New York (May 13, 2013, 3:02 PM EDT) -- The class alleging North China Pharmaceutical Group Corp. and its vitamin C unit fixed prices pushed back Friday against NCPG’s bid to dismiss the suit in New York federal court and toss a recent $153 million damages award, saying China didn’t compel the companies’ illegal conduct.

The direct purchaser damages class and the injunction class argue that evidence at trial and the jury verdict show that whether China forced the collusive conduct through regulations and the China Chamber of Commerce for Medicine and Health Products Importers...
To view the full article, register now.